Oranee Daniels

Oranee Daniels, MD, joined Antiva Bioscience in 2016, bringing more than 15 years of clinical research and drug development experience in the pharmaceutical industry. From 2009 to 2014, Oranee was Vice-President, Clinical Pharmacology and Experimental Medicine (CPEM) at Theravance, Inc. (THRX) where she oversaw clinical programs from INDs. Before Theravance, she had increasing responsibilities in Early Development and Clinical Pharmacology at Amgen, Inc (AMGN) and Eli Lilly (LLY), where she led and was involved with several successful programs in multiple therapeutic areas. She obtained her M.D. and completed her residency training in Internal Medicine at Chulalongkorn University, Thailand and holds a M.Sc. degree in Cardiovascular Pharmacology from McMaster University. She completed her Clinical Pharmacology fellowship at Stanford University and is board certified in Clinical Pharmacology.